It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
CVM’s FA Score shows that 0 FA rating(s) are green whileOPK’s FA Score has 0 green FA rating(s), and RDUS’s FA Score reflects 1 green FA rating(s).
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
CVM’s TA Score shows that 4 TA indicator(s) are bullish while OPK’s TA Score has 6 bullish TA indicator(s), and RDUS’s TA Score reflects 3 bullish TA indicator(s).
CVM (@Biotechnology) experienced а -4.07% price change this week, while OPK (@Medical Specialties) price change was +7.09% , and RDUS (@Steel) price fluctuated +0.34% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was +1.20%. For the same industry, the average monthly price growth was +0.43%, and the average quarterly price growth was -6.05%.
The average weekly price growth across all stocks in the @Medical Specialties industry was +1.36%. For the same industry, the average monthly price growth was +2.47%, and the average quarterly price growth was -2.30%.
The average weekly price growth across all stocks in the @Steel industry was -0.94%. For the same industry, the average monthly price growth was +1.04%, and the average quarterly price growth was -3.61%.
CVM is expected to report earnings on May 15, 2025.
OPK is expected to report earnings on Jul 31, 2025.
RDUS is expected to report earnings on Jun 25, 2025.
Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
@Medical Specialties (+1.36% weekly)Medical specialties are companies that make equipment used by the health care industry. Equipment manufactured and distributed by these companies include dialysis machines, blood analysis equipment, surgical equipment, dental instruments, and diagnostic tools, among other items. Large companies typically aim to produce and distribute high-quality products across a broad market spectrum. Smaller firms are more likely to specialize in a particular market segment. Due to the industry’s close association with medical treatments, they typically have low sensitivity to macroeconomic fluctuations. Within this industry, Abbott Laboratories, Medtronic Plc and Thermo Fisher Scientific Inc. are some of the companies with multi-billion market capitalizations in the U.S. stock markets.
@Steel (-0.94% weekly)The steel industry includes manufacturers of steel and steel-related products. Companies use iron ore and scrap steel to produce steel. The industry also includes companies involved in mining and marketing of steel products. Along with serving some of the domestic markets, U.S. steel output has, over the years, been used by international economies as well. Competition from imported steel has also increased over time. The industry could be susceptible to business cycles, since the element is an important input in industrial production. Some of the globally-renowned steel behemoths include Nucor Corporation, Vale, and ArcelorMittal SA.
CVM | OPK | RDUS | |
Capitalization | 7.4M | 920M | 833M |
EBITDA | -21.96M | -65.52M | -200.1M |
Gain YTD | -80.328 | -7.483 | 98.376 |
P/E Ratio | N/A | 26.11 | N/A |
Revenue | 0 | 863M | 2.74B |
Total Cash | N/A | 95.9M | 5.44M |
Total Debt | 11.1M | 327M | 562M |
CVM | OPK | RDUS | ||
---|---|---|---|---|
OUTLOOK RATING 1..100 | 51 | 5 | 77 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 98 Overvalued | 67 Overvalued | 12 Undervalued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | 68 | |
SMR RATING 1..100 | 98 | 90 | 94 | |
PRICE GROWTH RATING 1..100 | 98 | 80 | 36 | |
P/E GROWTH RATING 1..100 | 55 | 98 | 82 | |
SEASONALITY SCORE 1..100 | n/a | n/a | n/a |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
RDUS's Valuation (12) in the Biotechnology industry is somewhat better than the same rating for OPK (67) and is significantly better than the same rating for CVM (98). This means that RDUS's stock grew somewhat faster than OPK’s and significantly faster than CVM’s over the last 12 months.
RDUS's Profit vs Risk Rating (68) in the Biotechnology industry is in the same range as OPK (100) and is in the same range as CVM (100). This means that RDUS's stock grew similarly to OPK’s and similarly to CVM’s over the last 12 months.
OPK's SMR Rating (90) in the Biotechnology industry is in the same range as RDUS (94) and is in the same range as CVM (98). This means that OPK's stock grew similarly to RDUS’s and similarly to CVM’s over the last 12 months.
RDUS's Price Growth Rating (36) in the Biotechnology industry is somewhat better than the same rating for OPK (80) and is somewhat better than the same rating for CVM (98). This means that RDUS's stock grew somewhat faster than OPK’s and somewhat faster than CVM’s over the last 12 months.
CVM's P/E Growth Rating (55) in the Biotechnology industry is in the same range as RDUS (82) and is somewhat better than the same rating for OPK (98). This means that CVM's stock grew similarly to RDUS’s and somewhat faster than OPK’s over the last 12 months.
CVM | OPK | RDUS | |
---|---|---|---|
RSI ODDS (%) | 2 days ago81% | 2 days ago90% | 2 days ago81% |
Stochastic ODDS (%) | 2 days ago88% | 2 days ago85% | 2 days ago80% |
Momentum ODDS (%) | 2 days ago90% | 2 days ago77% | 2 days ago74% |
MACD ODDS (%) | 2 days ago90% | 2 days ago89% | N/A |
TrendWeek ODDS (%) | 2 days ago90% | 2 days ago75% | 2 days ago77% |
TrendMonth ODDS (%) | 2 days ago90% | 2 days ago78% | 2 days ago75% |
Advances ODDS (%) | 18 days ago81% | 18 days ago75% | 8 days ago76% |
Declines ODDS (%) | 2 days ago90% | 8 days ago80% | 2 days ago80% |
BollingerBands ODDS (%) | 2 days ago77% | 2 days ago81% | 2 days ago82% |
Aroon ODDS (%) | 2 days ago90% | 2 days ago77% | 2 days ago69% |
A.I.dvisor indicates that over the last year, OPK has been loosely correlated with ICUI. These tickers have moved in lockstep 38% of the time. This A.I.-generated data suggests there is some statistical probability that if OPK jumps, then ICUI could also see price increases.
Ticker / NAME | Correlation To OPK | 1D Price Change % | ||
---|---|---|---|---|
OPK | 100% | +4.62% | ||
ICUI - OPK | 38% Loosely correlated | +4.64% | ||
XAIR - OPK | 35% Loosely correlated | N/A | ||
CLPT - OPK | 33% Loosely correlated | -0.99% | ||
CRL - OPK | 33% Loosely correlated | +1.06% | ||
IQV - OPK | 33% Poorly correlated | +1.61% | ||
More |